Odyssey Therapeutics (ODTX) vs Sana Biotechnology (SANA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($870.8 million vs $835.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ODTX | SANA |
|---|---|---|
| Share price | $18.12 | $2.79 |
| Market cap | $870.82M | $835.22M |
| 1-day change | +0.22% | +2.57% |
| YTD return | — | -33.17% |
| 1-year return | — | -33.98% |
| 5-year return | — | -86.92% |
| EPS (TTM) | $-7.55 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.05 | $6.55 |
| 52-week low | $15.10 | $2.61 |
| Distance from 52-week high | -37.62% | -57.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +97.30% | +202.15% |
| Average volume | 270.92K | 3.10M |
| Shares outstanding | 48.06M | 299.36M |
| Employees | 100 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
About Sana Biotechnology
SANA stock →Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
ODTX vs SANA FAQ
Which is bigger, Odyssey Therapeutics or Sana Biotechnology?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $870.82M compared with $835.22M for Sana Biotechnology (SANA).
Are Odyssey Therapeutics and Sana Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.